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Background/Aims: Frequent pathogens of nosocomial meningitis were investigated and the adequacy of empiric 
antibiotic therapy was assessed. Outcomes of nosocomial meningitis were also evaluated. 
Methods: Ninety-one patients, who were diagnosed and treated for nosocomial meningitis at a single tertiary hospital 
in Daegu, Korea for 10 years, were included. Medical record and electronic laboratory data on the causative pathogens, 
antibiotics used, and outcomes were retrospectively investigated. 
Results: Coagulase-negative Staphylococcus (40.9%) was the most common pathogen, followed by Acinetobacter 
(32.5%). Both were cultured as a single organism in cerebrospinal fluid (CSF). Seventy-eight patients (85.7%) had 
infections related to external ventricular drains (EVD). The most common empirical antibiotics were extended-spectrum 
beta-lactam antibiotics plus vancomycin (35/91, 38.6%). Of the 27 patients who had cultured Acinetobacter in CSF, 10 
(37%) were given the wrong empirical antibiotic treatment. Seven of the 27 patients (26.9%) with cultured Acinetobacter 
died, and overall mortality of the 91 patients was 16.5%. In the multivariate analysis, the presence of combined septic 
shock (p < 0.001) and a persistent EVD state (p = 0.021) were associated with a poor prognosis.
Conclusions: Acinetobacter is one of the leading pathogens of nosocomial meningitis and may lead to inadequate 
coverage of empiric antibiotic therapy due to increasing resistance. An EVD should be removed early in cases of 
suspected nosocomial meningitis, and carbapenem might be required for the poor treatment response.
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INTRODUCTION
Nosocomial bacterial meningitis can be caused by in-
vasive procedures (e.g., craniotomy, placement of inter-
nal or external ventricular catheters, lumbar puncture, 
intrathecal infusion of medications, or spinal anesthe-
sia) and complicated head trauma [1]. Gram-positive 
pathogens such as methicillin-resistant coagulase-neg-
ative Staphylococcus (MRCNS) are the main target or-
ganisms to be controlled with empiric antibiotic therapy 
[2-11]. Gram-negative pathogens have increased as nos-
ocomial meningitis pathogens and should be considered 
in the choice of empirical antibiotic treatments [12]. The 
frequency of neurosurgical procedures is increasing and 
the wide use of broad spectrum antibiotics may have 
changed the causative pathogens of nosocomial menin-172    The Korean Journal of Internal Medicine Vol. 27, No. 2, June 2012
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gitis. Recently, Acinetobacter have been frequently re-
ported as the nosocomial meningitis causative pathogen 
[12]. Additionally, multidrug-resistant Acinetobacter 
baumannii infections are increasing [13]. The aim of 
this study was to investigate the frequency of the patho-
gens and to assess the adequacy of empiric antibiotic 
therapy for nosocomial meningitis. We also evaluated 
outcomes and prognoses for patients with nosocomial 
meningitis.
METHODS
Patients
Ninety-one patients, who were diagnosed with noso-
comial meningitis from December 27, 2000 to October 
29, 2010, were enrolled. We gained institutional review 
board approval (KNUH 2011-06-016) for this study. Pa-
tients were screened by positive results of cerebrospinal 
fluid (CSF) cultures using electronic hospital laboratory 
data. Nosocomial meningitis was defined as meningitis 
acquired after 48 hours of admission. The diagnosis of 
meningitis was made if all of the following criteria were 
fulfilled: 1) at least one pathogen was cultured in CSF, 
2) increased white blood cell (WBC) count (> 10/high 
power field) with dominant polymorphonuclear leuko-
cytes (> 50%), and 3) body temperature > 38°C that was 
not from other causes [14,15].
Methods 
The admission site was defined as the site (the ward 
or intensive care unit) of the meningitis from the clini-
cal symptom presentation. Septic shock was identified if 
there was severe sepsis plus one or both of the following 
systemic mean blood pressures: < 60 mmHg or < 80 
mmHg if the patient had baseline hypertension, despite 
adequate fluid resuscitation [16]. WBC counts and levels 
of protein and glucose in CSF were investigated. Pa-
tients who had a continuous external ventricular drain 
(EVD) catheter after they were diagnosed with meningi-
tis were defined as in a persistent EVD state. A negative 
CSF culture was defined as a negatively converted CSF 
culture after at least three follow-up cultures following 
the first positive result in CSF [17,18]. Empirical anti-
biotics were defined as antibiotics used immediately 
after the onset of the suspected or established clinical 
diagnosis to the time of the culture report, and specific 
antibiotics that changed or continued after the meningi-
tis pathogens were discovered. The outcomes and dura-
tion of follow-up from admission date to the last visit or 
death date were also determined.
Statistical analyses
Descriptive statistics were performed, and univari-
ate analyses with variables related to death were tested 
by the chi-square method for non-continuous variables 
and the t test for continuous variables. A multivariate 
logistic regression test was performed to identify risk 
factors for death. Variables with a p value < 0.2 in the 
univariate analysis were included in the multivariate 
analysis. A p value < 0.05 was considered significant. 
RESULTS
Demographic and clinical characteristics
Of the 91 patients, ages ranged from 19 to 83 years 
(average age, 52.6). The duration from admission was 
8-1,519 days (average duration, 90.3). Ten patients (11%) 
had diabetes mellitus as an underlying disease. Table 
1 shows the patient demographic characteristics and 
underlying diseases. All patients had neurological prob-
lems. The most frequent causes of admission were: 41 
patients (52.7%) had cerebral hemorrhage, 17 (18.7%) 
had a brain tumor, and six (6.6%) suffered from a trau-
matic head injury. Seventy-eight (85.7%) patients devel-
oped EVD-related infections. Thirteen patients (14.3%) 
had other predisposing factors for meningitis. The 
predisposing nosocomial meningitis factors are sum-
marized in Table 2, and the CSF cultured organisms are 
shown in Table 3. 
Antibiotic regimens 
All 91 patients were treated with empirical anti-
biotics. Extended spectrum beta-lactam antibiotics 
plus vancomycin was the most favorable empirical 
regimen (35/91, 38.6%). Among them, ceftazidime 
plus vancomycin was administered to 24/35 patients 
(68.6%) and ceftriaxone plus vancomycin to 8/35 pa-
tients (22.9%). The resistance and sensitivity of each 
antibiotic to Acinetobacter were as follows: ceftriax-
one, 40.7/3.7/25.9/0% (S/I/R/unknown), respectively; Kim HI, et al. Nosocomial meningitis   173
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ceftazidime, 22.2/3.7/25.9/51.9% (S/I/R/unknown); 
cefepime, 59.3/0/37/3.7% (S/I/R/unknown); imipe-
nem, 70.4/3.7/25.9/0% (S/I/R/unknown); and colistin, 
14.8/85.2% (S/unknown). Table 4 shows a summary of 
the antibiotic susceptibilities for Acinetobacter spp. in 
CSF culture.
Clinical courses and prognoses
Seventy-three patients (93.6%) with EVD-related 
meningitis had their EVD catheters removed, and five 
(6.4%) had a persistent EVD catheter. We had difficulty 
removing the EVD from all patients due to difficulties 
controlling the increased intracranial pressure. Sev-
enty patients (76.9%) showed a negative conversion on 
CSF culture with therapy, 10 patients (11%) showed a 
persistent positive culture after therapy, and 11 patients 
(12.1%) were unknown. The duration from the onset 
of diagnosis to a negative CSF culture was 1-146 days 
(average duration, 11.75 days). Of the 91 patients, 15 
(16.5%) died, 72 (79.1%) survived, and four (4.4%) had 
unknown outcomes. The follow-up duration varied from 
1-3,024 days (average follow-up, 683.8 days). In the chi-
square analysis, male gender (p = 0.034; odds ratio [OR], 
4.0), persistent EVD state after diagnosis of meningitis 
(p = 0.009; OR, 7.0), combined septic shock (p < 0.001; 
OR, 32.5), and C-reactive protein > 10 mg/dL (p = 0.012; 
OR, 4.4) were associated with a poor prognosis (Table 
5). Acinetobacter in the CSF culture (p = 0.119; OR, 
2.4) and discordant empirical antibiotic treatment (p = 
0.177; OR, 2.2) were not statistically significant in the 
univariate analysis. Combined septic shock (p < 0.001; 
OR, 108.4) and persistent EVD state (p = 0.021; OR, 
11.9) were related to higher mortality in the multivariate 
Table 1. Clinical characteristics of the patients with 
nosocomial meningitis
Characteristics No. (%)
Sex
Male    50 (54.9) 
Female    41 (45.1)
Admission site 
General ward    28 (30.8)
Intensive care unit    63 (69.2)
Underlying disease
Yes    36 (39.6)
Malignancy    16 (17.6)
Cerebrovascular disease    12 (13.2)
Diabetes mellitus    10 (11.0)
Chronic renal disease      3 (3.3)
Chronic obstructive pulmonary disease      2 (2.2) 
Chronic liver disease      2 (2.2)
Steroid medication history      1 (1.1)
No    53 (58.2)
Unknown      2 (2.2)
Mental status 
Alert      6 (6.6)
Drowsy    31 (34.1)
Stupor    26 (28.6)
Semicoma    10 (11.0)
Coma       2 (2.2)
Unknown    16 (11.4)
Combined septic shock
Yes 14 (15.4)
No 73 (80.2)
Unknown   4 (4.4)
Cerebrospinal fluid Gram stain
Gram-positive pathogens 28 (30.8)
Gram-negative pathogens 26 (28.6)
Both  11 (12.1)
Not seen 26 (29.1)
Cerebrospinal fluid culture 
Single organism 83 (91.2)
Multiple organism   8 (8.8)
Combined bacteremia
Yes 16 (17.6)
No 75 (82.4)
Combined nosocomial infection 
Yes 24 (26.4)
Urinary tract infection 11 (42.3)
Pneumonia   7 (26.9)
Catheter related infection   1 (3.8)
Pseudomembranous colitis   1 (3.8)
Deep neck infection   1 (3.8)
Urinary tract infection + catheter-related 
infection
  1 (3.8)
Urinary tract infection + pneumonia   2 (7.6)
No 66 (72.5)
Unknown   1 (1.1)
Total   91 (100) 
Table 2. Predisposing conditions of the 91 patients 
with nosocomial meningitis
Disease No. (%)
External ventricular drainage 78 (85.7)
Craniotomy (cerebral hemorrhage, brain tumor) 7 (7.7)
Wound infection of craniotomy 2 (2.2)
Ventriculo-peritoneal shunt operation 2 (2.2)
Basal skull fracture 1 (1.1)
Paravertebral nerve block 1 (1.1)
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logistic regression analysis (Table 5). 
Organisms that were cultured for 10 years are shown 
in Fig. 1. Acinetobacter meningitis did not show a 
changing incidence pattern and had an endemic pat-
tern. Table 6 summarizes the adequacy and outcomes 
of the empirical antibiotic treatments against a single 
pathogen in CSF culture. Thirty-five patients (38.5%) 
were treated with inappropriate empirical antibiotics, 
and their specific antibiotics were changed based on 
the culture report. MRCNS revealed 23.1% discordant 
empirical antibiotics, Acinetobacter revealed 37%, and 
methicillin-resistant S. aureus showed 37.5%. The mor-
tality from Acinetobacter meningitis was high at 26.9%.
DISCUSSION
Beer et al. [19] showed that Staphylococcus epidermi-
dis (70%) and Staphylococcus aureus (10%) are com-
mon causative pathogens in patients with EVD-related 
meningitis. Coagulase-negative Staphylococcus was 
the most common pathogen of EVD-related meningitis 
in previous studies [20-22]. In our study, coagulase-
negative Staphylococcus was also the most frequent 
pathogen (34/83, 40.9%), focusing on single-organism 
meningitis in CSF. Palabiyikoglu et al. [23] reported 
CSF cultures of 49 patients who were diagnosed with 
adult nosocomial meningitis; 61% of the patients had 
proven Gram-negative pathogens in a CSF study, and 
34% had Gram-positive pathogens. 
 Acinetobacter spp. seem to be increasingly important 
pathogens associated with postneurosurgical menin-
gitis [18]. In our study, Acinetobacter meningitis did 
not show increased prevalence in the last several years; 
however, it was proved in 27 patients (32.5%) as the 
second most common cause. These findings remind of 
us that recent significant increases in Gram-negative 
pathogens such as Acinetobacter should be considered 
when managing patients with nosocomial meningitis. 
Our results and those of previous studies [18,23] sug-
gest that a long intensive care unit stay and invasive 
procedures such as EVD, craniotomy, wound infections, 
shunts, basal skull fractures, and spinal anesthesia may 
be important risk factors for Acinetobacter meningitis. 
Many patients with meningitis have EVD after neuro-
surgery. Erdem et al. [12] reported that 63% of patients 
develop EVD difficulties. Katragkou and Roilides [24] 
reported nine patients diagnosed with A. baumannii 
meningitis, and five had an EVD. EVD-related men-
ingitis was also the most common type of nosocomial 
meningitis in our study with 78 patients infected 
(85.7%). Therefore, these findings reconfirm that inva-
sive procedures such as EVD are strongly related to the 
incidence of nosocomial meningitis. Additionally, physi-
cians should consider that early removal of an EVD is 
important for a favorable outcome in cases of suspicious 
meningitis in hospitalized patients. 
Rodriguez Guardado et al. [13] reported 51 patients 
Table 3. Microbiology of the cerebrospinal fluid culture 
in the 91 patients with monoorganism culture-positive 
nosocomial meningitis
a
Pathogen No. (%)
Coagulase negative Staphylococcus 34 (40.9)
MSCNS 26 (31.3)
MRCNS 8 (9.6)
Acinetobacter 27 (32.5)
Acinetobacter baumannii  26 (31.3)
Acinetobacter lowfflii 1 (1.2)
Staphylococcus aureus 10 (12.0)
MSSA 2 (2.4)
MRSA 8 (9.6)
Enterococcus species 5 (6.0)
Serratia marcescens 2 (2.4)
Strepcococcus agalactiae 1 (1.2)
Bordetella bronchiectasia 1 (1.2)
Enterobacter species 1 (1.2)
Pseudomonas fluorescens 1 (1.2)
Stenotrophomonas maltophilia 1 (1.2)
Total 83 (100)
MSCNS, methicillin sensitive coagulase negative Staphylococ-
cus; MRCNS, methicillin resistant coagulase negative Staphy-
lococcus; MSSA, methicillin-sensitive Staphylococcus aureus; 
MRSA, methicillin-resistant Staphylococcus aureus. 
aEight patients showed multiple organisms in the cerebrospinal 
fluid culture as follows: A. baumannii, E. coli and MSCNS (1), 
Enterococcus and S. maltophilia (1), Enterococcus and MRCNS 
(1), Enterococcus and MRSA (1), Enterococcus, MRCNS and 
S. maltophilia (1), Enterococcus, A. baumannii, P. aerusinosa, 
Enterobacter, E. coli, S. maltophilia and Providencia rettgeri (1), 
Enterococcus, Klebsiella pneumoniae and α-hemolytic Strepto-
coccus (1), Acinetobacter, MRCNS (1).Kim HI, et al. Nosocomial meningitis   175
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Table 4. Antibiotic susceptibility of Acinetobacter discovered in cerebrospinal fluid cultures from patients with 
nosocomial meningitis
Antibiotics
Susceptibility (%)
Susceptible Intermediate Resistant Unknown
Ampicillin/sulbactam 14 (51.9) 0   7 (25.9)   6 (22.2)
Aztreonam 11 (40.7) 2 (7.4) 12 (44.4)   2 (7.4)
Cefepime 16 (59.3) 0 10 (37)   1 (3.7)
Cefotaxime   1 (3.7) 0   5 (18.5) 21 (77.8)
Ceftriaxone 11 (40.7) 1 (3.7)   7 (25.9)   0
Ceftazidime   6 (22.2) 0   7 (25.9) 14 (51.9)
Ciprofloxacin 15 (55.6) 0 12 (44.4)   0
Colistin   4 (14.8) 0   0 23 (85.2)
Gentamicin 11 (40.7) 2 (7.4)   8 (29.6)   6 (22.2)
Imipenem 19 (70.4) 1 (3.7)   7 (25.9)   0
Levofloxacin   0 1 (3.7)   3 (11.1) 23 (85.2)
Minocycline   4 (14.8) 0   0 23 (85.2)
Piperacillin   8 (29.6) 0   8 (29.6) 11 (40.7)
Piperacillin/tazobactam 16 (59.3) 1 (3.7)   8 (29.6)   2 (7.4)
Ticarcillin   1 (3.7) 0   4 (14.8) 22 (81.5)
Tobramycin 12 (44.4) 3 (11.1) 11 (40.7)   1 (3.7)
Trimethoprim/sulfamethoxazole 15 (55.6) 0 12 (44.4)   0
100
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with EVD-related meningitis after neurosurgery. All 
patients were treated with empirical antibiotics, and the 
therapy was appropriate in 42% of patients. Treatment 
was changed in five patients because of inappropriate 
antibiotics, 27 patients were treated with single intrave-
nous antibiotics, and carbapenem was the most common 
specific antibiotic regimen (21 patients) [13]. In contrast, 
vancomycin plus ceftazidime was the most frequent 
empirical combination regimen used in our study. This 
regimen was used considering Gram-positive pathogens 
such as MRCNS and Gram-negative pathogens such as 
Pseudomonas. However, Gram-negative pathogens such 
as ceftazidime-resistant Acinetobacter must not be ig-
nored. A recent study conducted with 2,621 collected 
Acinetobacter isolates showed that 44.6% were suscep-
tible to ceftazidime, and 47.7% were susceptible to ce-
fepime [25]. Acinetobacter shows frequent resistance to 
third- and fourth-generation cephalosporins and even 
to carbapenems [18]. Thus, intravenous meropenem, 
with or without an aminoglycoside administered via the 
intraventricular or intrathecal route, has been recom-
mended for empirically treating Acinetobacter menin-
gitis [18]. If the organism is subsequently found to be 
resistant to carbapenems, then colistin or polymyxin B 
should be substituted for meropenem and may need to 
be administered via the intraventricular or intrathecal 
route [26]. In this study, resistance of invasive Acineto-
bacter isolated in the CSF to ceftazidime and cefepime 
was significant. The resistance of carbapenem was lower 
than that of other antibiotics. The percentage of total 
misused empirical antibiotics (38.5%) was lower than 
that in a previous study [13]; however, 10 of the 27 inap-
propriate treatments (37%) were significant for Acineto-
bacter in this study. Carbapenem must be considered a 
therapeutic antibiotic when poor treatment outcome in 
Acinetobacter meningitis.  
Erdem et al. [12] reported that nine (52.9%) of 17 pa-
tients died from Acinetobacter meningitis. Rodriguez 
Guardado et al. [13] reported on 51 patients with EVD-
related Acinetobacter meningitis and 17 patients died 
from the infection. In a multivariate analysis, mortality 
shows a relationship with age, WBC counts, and re-
moval of EVD alone [13]. In our study, mortality from 
Acinetobacter meningitis was high and the reported 
Table 5. Chi-square, univariate, and multivariate logistic regression analyses for the characteristics between the 91 
dead and surviving patients with nosocomial meningitis
Characteristics p value OR
95% CI
Lower limit Upper limit
The chi-square univariate
 analysis
Age > 60 yr 0.065 0.3 0.08     1.14
Male gender 0.034 4.0 1.04   15.38
ICU admission (at presentation) 0.124 3.3 0.68   15.58
Semicoma or comatous mental state 0.124 2.9 0.72   11.64
Causative pathogens
CNS 0.096 0.3 0.09     1.27
Staphylococcus aureus 0.542 1.7 0.31    9.33
Acinetobacter 0.119 2.4 0.78      7.65
Persistent EVD 0.009 7.0 1.38   35.88
Combined septic shock  < 0.001 32.5 6.89 153.33
Glucose (CSF) < 30 mg/dL 0.607 0.7 0.20     2.58
WBC (CSF) > 300/mm
3 0.065 3.4 0.88   13.02
CRP ≥ 10 mg/dL 0.012 4.4 1.31   14.60
Discordant empirical antibiotics treatment 0.177 2.2 0.70    6.61
Multivariate logistic  
 regression test (forward)
Persistent EVD 0.021 11.9 1.46   97.62
Combined septic shock  < 0.001 108.4 9.91 1184.82
OR, odds ratio; CI, confidence interval; ICU, intensive care unit; CNS, coagulase negative staphylococcus; EVD, extraventricular drain; 
CSF, cerebrospinal fluid; WBC, white blood cells; CRP, C-reactive protein.Kim HI, et al. Nosocomial meningitis   177
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poor prognostic factors [13] such as CSF, WBC count, 
glucose level, age, and mental status were not associated 
with higher mortality; additionally, we failed to identify 
the relationship between duration from admission and 
diagnosis or treatment and antibiotic regimens, labora-
tory factors, and mortality from nosocomial meningitis. 
Removing the EVD is an important factor for increasing 
the cure rate of nosocomial meningitis [18]. Addition-
ally, the relationship between the persistent EVD state, 
combined with septic shock and poor outcomes, was 
statistically significant. Early removal of the EVD and 
aggressive antibiotic treatment for suspected nosocomi-
al meningitis would lead to better outcomes. This study 
involved a single-center analysis, so generalization is 
difficult, and a multicenter study is needed.
Nosocomial meningitis is rare, but treatment is dif-
Table 6. Empirical antibiotic treatment regimens against a single pathogen in cerebrospinal fluid (CSF) culture, 
treatment success rate, and outcomes of patients
Cultured organism (CSF) Empirical antibiotics
Discordant 
empirical 
antibiotics (%)
Alive (%) Total
B. bronchiseptia Ceftazidime + vancomycin  (1, 100%)     1 (100) 1 (100) 1
S. agalactiae Ampicillin + ceftriaxone + vancomycin (1, 100%)             0 1 (100) 1
S. marcense Ceftazidime + vancomycin (1, 50%),  ceftriaxone + vancomycin (1, 
50%)
            0 2 (100) 2
A. lowffli Vancomycin (1, 100%)     1 (100) 1 (100) 1
P. fluorescens Ceradoran + fortimicin (1, 100%)             0     0  1
MRCNS Ceftazidime + vancomycin (2, 25%), vancomycin (2, 25%), ceftriax-
one + vancomycin (1, 12.5%), ceftriaxone + metronidazole (1, 12.5%), 
imipenem + vancomycin (1, 12.5%), vancomycin + rifampin (1, 12.5%)
     3 (37.5) 8 (100) 8
S. maltophilia Ticarcillin/clavulanic acid + amphotericin (1, 100%)     1 (100)     0 1
Enterobacter species Ceftazidime + vancomycin (1, 100%)             0 1 (100) 1
A. baumannii Ceftazidime + vancomycin (6, 22.2%), ceftriaxone (3, 11.1%), me-
ropenem (3, 11.1%), ceftriaxone + vancomycin (2, 7.4%), ceftriaxone + 
metronidazole (2, 7.4%), cefotaxime (2, 7.4%), piperacillin/tazobactam 
(2, 7.4%), ceftriaxone + fortimicin (1, 3.7%), ceftazidime (1, 3.7%), ampi-
cllin/sulbactam + ciprofloxacin (1, 3.7%), meropnem + vancomycin + 
amikacin (1, 3.7%), vancomycin + teicoplanin (1, 3.7%), vancomycin + 
tobramycin (1, 3.7%), vancomycin (1, 3.7%)
     9 (34.6) 19 (70.4) 26
Enterococcus species Ceftazidime + vancomycin (2, 40%), cefotaxime + metronidazole (1, 
20%), ceftriaxone + vancomycin (1, 20%), vancomycin (1, 20%)
  4 (80) 4 (80) 5
MRSA Cefminox + amikacin (1, 12.5%), cefotaxime + vancomycin + rifampin (1, 
12.5%), cefotaxime + teicoplanin (1, 12.5%), cefotaxime + vancomycin 
+ fortimicin (1, 12.5%), cefotaxime + monobactam (1, 12.5%), ceftri-
axone + vancomycin (1, 12.5%), ceftriaxone + fortimicin (1, 12.5%), 
ceftazidime + vancomycin(1, 12.5%)
  4 (50) 8 (100) 8
MSCNS Ceftazidime + vancomycin (5, 19.2%), vancomycin (5, 19.2%), cefo-
taxime (3, 11.5%), ceftriaxone (2, 7.7%), ceftriaxone + vancomycin 
(2, 7.7%), vancomycin (2, 7.7%), cefepime + vancomycin (2, 7.7%), 
piperacillin/tazobactam + vancomycin (2, 7.7%), meropenem + vanco-
mycin (1, 3.8%), meropenem + vancomycin + metronidazole (1, 3.8%), 
piperacillin/tazobactam + teicoplanin + tobramycin (1, 3.8%)
    6 (23.1) 23 (88.5) 26
MSSA Ceftazidime + vancomycin (2, 100%)   1 (50)     0 2
Total 83
MRCNS, methicillin resistant coagulase negative Staphylococcus; MRSA, methicillin-resistant Staphylococcus aureus; MSCNS, methi-
cillin-sensitive coagulase negative Staphylococcus; MSSA, methicillin-sensitive Staphylococcus aureus.  178    The Korean Journal of Internal Medicine Vol. 27, No. 2, June 2012
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ficult because of the increasing number of multidrug 
resistant Gram-negative pathogens. Acinetobacter is an 
increasingly prevalent causative pathogen, antibiotic re-
sistance occurs frequently, and mortality was high. We 
think that vancomycin plus ceftazidime as a traditional 
empirical treatment regimen may not completely cover 
all current nosocomial meningitis pathogens. We sug-
gest an immediate change to antibiotics with high activ-
ity against resistant Acinetobacter to adequately treat 
nosocomial meningitis. 
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